KRAS and BRAF Hotspot Variants Show Lower Prevalence in Bangladeshi Colorectal Cancer Patients.

Authors

Muhammad Sibgatullah Zunnun, Md Zahin Alam, S M Mahbubur Rashid, Md Shihab Al Mashiur Rahaman, Nahid Parvez, Md Shahadot Hossain Sheikh, Farida Arjuman, Mustak Ibn Ayub

Published in

Asian Pacific journal of cancer prevention : APJCP. Volume 27. Issue 9. Pages 3221-3226. Sep 01, 2026. Epub Sep 01, 2026.

Abstract

Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality globally, with a rising incidence in Bangladesh. This study aims to identify pathogenic KRAS and BRAF mutations contributing to anti-EGFR resistance in CRC patients.
Two sets of primers were used: one was adopted from a published paper, and another was designed using Primer3Plus. They were optimized for specific PCR amplicons of 173 bp and 230 bp from exon 2 of KRAS and exon 15 of BRAF, respectively. Targeted Sanger sequencing was performed to analyze mutations in these amplicons in 46 CRC patient samples.
KRAS mutations were detected in 5 samples (10.87%), comprising two G12D, one G12V, and two G13D variants. Notably, no BRAF V600E mutation was identified. These results stand in sharp contrast to global data, where KRAS mutations at these loci occur in approximately 40% of cases and BRAF V600E mutations in about 10%. Such mutations are clinically significant because they confer resistance to anti-EGFR therapy, underscoring the distinct molecular profile observed in this cohort.
The lower prevalence of KRAS and BRAF mutations indicates the potential effectiveness of anti-EGFR therapies in Bangladeshi CRC patients than other populations.

PMID:
42808388
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.